Non Steroid for TRT
- 10-15-2007, 01:34 PM
Non Steroid for TRT
The search for alternatives to steroid medications for treating millions of Baby Boomer males with age-related declines in the sex hormone testosterone has led researchers in California to report development of a nonsteroidal compound that shows promise as a new treatment for loss of muscle mass, bone tissue, and other problems linked to low testosterone. .
In the report, Arjan van Oeveren and colleagues point out that the potential side effects of testosterone, a steroid medication, limit its use to older men with low testosterone levels. Testosterone replacement therapy may increase the risk of prostate cancer and stroke, for instance, and cannot be given orally. People take it via skin patches or rub-on gels.
The new study describes a nonsteroidal compound that in lab rats attaches to testosterone receptors in cells and triggers the same desired effects as actual testosterone in tests in laboratory animals. In comparison to other testosterone replacement treatments, the compound showed similar improvement in muscle mass and strength while having little effect on the prostate, the researchers say. It also significantly improved bone density and strength in the lab rats.
This study, "Substituted 6-(1-Pyrrolidine) quinolin-2(1H)-ones as Novel Selective Androgen Receptor Modulators," will appear in the Oct. 18 issue of the ACS' Journal of Medicinal Chemistry.
- 10-15-2007, 05:05 PM
- 10-18-2007, 04:42 PM
I've done some quick searches to find a company doing SARM research. Here is what I've found on news.moneycentral.msn.com:
Ligand Pharmaceuticals Incorporated LGND (the "Company" or "Ligand") today announced that an article authored by a team of Ligand scientists will appear in the October 18th issue of the Journal of Medicinal Chemistry and is also highlighted in a recent press release from the American Chemical Society (ACS).
The article, entitled "Substituted 6-(1-Pyrrolidine)quinolin-2(1H)-ones as Novel Selective Androgen Receptor Modulators (SARMs)" describes the development of a nonsteroidal compound, LGD-2941 that shows promise as a new treatment for loss of muscle mass, bone tissue and other problems linked to aging.
10-18-2007, 04:50 PM
- 5'10" 180 lbs.
- Join Date
- Sep 2003
- Rep Power
- Lv. Percent
SARMs will be the next big thing. I'm betting they sell as big as Viagra once someone isolates the magic molecules.
10-18-2007, 05:56 PM
10-20-2007, 09:36 PM
I'd still rather replace what's missing, not try to substitute with something else.
10-22-2007, 11:20 PM
Amen to that, Bro'
Study done by the people who will be marketing this product?
Like "studies" done by makers of AndroGel???
Testosterone side effects... (talkin' about pharmaceutical doses here - NOT steroidal doses as used in BB)... what freakin' side effects?
This is a joke....
Testosterone - the bio-identical variety - is just like your body's own hormone... and provides (in pharmaceutical doses) numerous health problems.. not just for gaining muscle or helping libido or helping with EC.
Thanks... but no thanks!
10-23-2007, 12:14 AM
10-31-2007, 01:23 PM
GTx inc is planning phaseIII trials on ostarine (SARM).
Builds muscle,promotes bone strength,enhances libido,increases fertility
Does not: stimulate prostate cancer,virilization,acne
What is involved in testing this? Anybody?
10-31-2007, 03:18 PM
Usually has the trial, who is running it and what the requirements are. A quick search didn't turn up anything for ostarine, but maybe a more throrough look will turn something up.
Let us know what you find.
11-01-2007, 03:41 PM
Injected testosterone has long term negative effects on future natural testosterone production. Do sarms have the same problem?
11-06-2007, 01:21 PM
11-06-2007, 02:24 PM
GTx, Inc., the Men's Health Biotech Company, today announced that ostarine, a first-in-class selective androgen receptor modulator (SARM), met its primary endpoint in a Phase II proof of concept double blind, randomized, placebo controlled clinical trial in 120 subjects...
(60 elderly men and 60 postmenopausal women)...
A summary of the topline data is as follows:
Primary endpoint: total lean body mass (LBM) measured by dual energy x-ray absorptiometry (DEXA) at baseline compared to three months
-- Among all subjects (n=114), ostarine treatment resulted in a dose dependent increase in total lean body mass, with an increase of 1.3 kg compared to baseline and 1.4 kg compared to placebo (p<0.001) at the 3 mg dose. (Note: This is 2.86 pounds and 3.08 pounds respectively.... for a time period of THREE months... a good diet program and exercise program could have easily beat out those figures!)
-- Among females (n=56), ostarine treatment resulted in a dose dependent increase in LBM with the 3 mg dose having an increase of 1.7 kg compared to baseline and an increase of 1.4 kg compared to placebo (p=0.02). (Note: That is 3.74 pounds and and 3.08 pounds respectively.... for a time period of THREE months... a good diet program and exercise program could have easily beat out those figures!)
-- Among males (n=58), treatment with a 1 mg dose of ostarine resulted in a LBM increase of 0.7 kg compared to baseline and an increase of 1.2 kg compared to placebo (p=0.03), and treatment with a 3 mg dose of ostarine resulted in an increase of 1.0 kg compared to baseline and an increase of 1.4 kg compared to placebo (p=0.005). (Note: Simply shows that the drug is highly dose dependant))
Secondary endpoints: performance, fat mass, bone mineral density, and bone turnover markers
-- In a stair climb functional performance test that measured speed (time to completion) and power exerted (watts), subjects treated with a 3 mg dose of ostarine demonstrated on average a 15.5% faster time to completion (p=0.006) and exerted on average 25.5% more power (p=0.005) than subjects receiving placebo. (Note: Again, simple dietary programs emphasizing protein and proper fats combined with resistance training can readily beat out those figures.)
-- Total tissue percent fat decreased compared to placebo in a dose dependent fashion and achieved statistical significance at the 1 mg dose (p=0.02) and 3 mg dose (p=0.006) of ostarine. Total fat mass was lower in subjects receiving either the 3 mg or 1 mg ostarine dose, although not at a statistically significant level (p = 0.08 for both doses). For subjects receiving the 3 mg ostarine dose, total fat on average declined 0.6 kg compared to placebo. The site of fat loss differed among male and female subjects, with males losing fat primarily from the trunk and abdomen, and females losing fat primarily from the thighs and legs. (Note: That is a grand total of 1.32 lbs in a THREE MONTH time period... again, a good dietary regimen and exercise program - even at a moderate level - would beat the pants off of those figures)
-- In this trial, ostarine had no apparent effect on bone mineral density, and bone turnover markers results were mixed.
Yet my prediction is that with their slick sales campaigns, they will make a fortune out of selling this product - to an ultimately highly disappointed patient group.
11-06-2007, 06:00 PM
11-06-2007, 07:25 PM
11-06-2007, 07:53 PM
Has Libido been studied?
I believe it could be used in both men and women.
02-28-2011, 03:27 PM
I have not felt any suppressive properties regarding libido, but I am just now starting to note an upsurge in muscle fullness during the workout and a slight fat loss effect - it hasn't been that long yet.
Similar Forum Threads
- By Mikemas in forum Male Anti-Aging MedicineReplies: 15Last Post: 05-08-2013, 01:59 PM
- By x_muscle in forum AnabolicsReplies: 347Last Post: 02-04-2009, 06:47 PM
- By freakabe in forum SupplementsReplies: 12Last Post: 11-29-2007, 10:58 AM
- By kropotkin in forum AnabolicsReplies: 25Last Post: 08-24-2004, 04:32 PM
- By wojo in forum AnabolicsReplies: 7Last Post: 01-10-2003, 12:01 PM